Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant

Tatiana Prokaeva
Boston University

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Female Urogenital Diseases and Pregnancy Complications Commons, Genetic Phenomena Commons, Genetics and Genomics Commons, Male Urogenital Diseases Commons, Nephrology Commons, and the Nutritional and Metabolic Diseases Commons

Repository Citation
Prokaeva T, Akar H, Spencer B, Havasi A, Cui H, O'Hara CJ, Gursky O, Leszyk JD, Steffen M, Browning S, Rosenberg A, Connors LH. (2017). Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant. Open Access Publications by UMass Chan Authors. https://doi.org/10.1016/j.ekir.2017.07.009. Retrieved from https://escholarship.umassmed.edu/oapubs/3317

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant

To the Editor: Systemic amyloidosis is characterized by the extracellular deposition of misfolded proteins as insoluble amyloid fibrils in various tissues. The familial forms of amyloidosis (AF) comprise a group of autosomal dominant diseases associated with mutations in a number of genes encoding amyloid precursor proteins. These diseases collectively exhibit various phenotypes, including ages of onset, organ involvements, rates of progression, and prognoses. Hereditary non-neuropathic, renal amyloidosis was first reported by Ostertag; since that report, mutations in lysozyme, fibrinogen A-α chain, transthyretin, gelsolin, apolipoprotein (apo) A-I, A-II, A-IV, C-II, and C-III have been linked to the disease. apoA-II Amyloidosis (AApoAII) is an exceedingly rare form of AF; only 3 APOA2 mutations have been reported in 4 families worldwide. In each case, a nucleotide replacement at the stop codon of APOA2 resulted in a variant apoA-II with a 21-residue C-terminal extension, 78Argext21, 78Serext21, and 78Glyext21.

Human apoA-II (77 amino acids, 17 kDa) is expressed in the liver and is found as a disulfide-linked homodimer in circulation. Nearly all circulating wild-type apoA-II is strongly bound to plasma high-density lipoprotein (HDL) via the unusually large apolar faces of its amphipathic α-helices. Similar to other exchangeable apolipoproteins, lipid-bound apoA-II acquires a highly amphipathic structure on HDL. Strong binding to HDL makes wild-type apoA-II practically nonexchangeable and protected from misfolding in vivo. However, in the absence of bound lipids in vitro, apoA-II becomes largely unfolded and labile to misfolding and proteolysis. Therefore, a population shift from HDL-bound to HDL-unbound apolipoprotein is thought to augment the development of AApoAII amyloidosis. Notably, apoA-II is the most hydrophobic member of the apolipoprotein family with the highest predicted propensity to form amyloid.

Here, we report a family with renal amyloidosis associated with a novel stop codon mutation in APOA2 and the apoA-II variant, 78Leuext21.

RESULTS

Clinical Presentation

The proband (Figure 1, II-4), a 45-year-old woman, was seen in the Amyloidosis Center at Boston University School of Medicine for evaluation. At age 41 years, she was found to have elevated creatinine at 1.5 mg/dl. At age 44, she developed bilateral leg swelling, blood pressure of 240/140, serum creatinine of 10 mg/dl, and 24-hour proteinuria of 13 g. Soon thereafter, she was started on hemodialysis. Because of labile hypertension, she underwent a left nephrectomy at age 45 years; histological examination revealed amyloid deposits. A workup was negative for monoclonal gammopathy or amyloid involvement of other organs. A bone marrow biopsy and an abdominal fat pad aspirate were negative for amyloid deposits. At age 46, she underwent cadaveric renal transplantation and right nephrectomy; histological examination again showed renal amyloid deposition. The posttransplantation course was uncomplicated; treatment has included CellCept, Prograft, and prednisone.

Evaluation at 18 months postrenal transplantation was completely unremarkable; blood pressure was 110/70, and serum creatinine was normal at 1.1 mg/dl with no proteinuria. There were no episodes of allograft rejection or signs of extrarenal organ involvement. At age 54 years, a fat pad biopsy revealed a small focus of amyloid deposits. Currently, at age 60, she has evidence of slowly worsening allograft dysfunction with serum creatinine of 1.8 mg/dl and 24-hour proteinuria of 118 mg. Her blood pressure is 113/74; she exhibits no signs of extrarenal involvement.

The father of the proband (Figure 1, I-1), originally from the Philippines, had a history of hypertension and died of gastrointestinal bleeding at age 59 years. The mother (I-2) was of Portuguese descent and had a history of hypertension and diabetes; she died of stroke at age 74. Siblings include 3 brothers and 2 sisters; none have a history of renal disease.

The proband has 2 children. The daughter (III-1) was diagnosed with renal amyloidosis at age 30; her serum creatinine was 0.9 mg/dl and 24-hour urine protein measured 2.7 g at disease presentation. She was started on dialysis at age 36 and underwent cadaveric renal transplantation at age 39. She has been treated with CellCept and Prograft, and has had no episodes of graft rejection. Currently, at age 41, her serum creatinine is 1.75 mg/dl, urine protein is below the measurable range, and she has no signs of extrarenal involvement.
The son (III-2) was diagnosed with renal amyloidosis at age 33 with serum creatinine of 1.45 mg/dl and 24-hour proteinuria of 7.4 g. At age 35, he started on peritoneal dialysis. Currently at age 36, he shows no sign of extrarenal involvement and is wait-listed for a cadaveric kidney transplant.

Histological Detection and Immunohistochemical Typing of Amyloid Deposits

Light microscopy of a renal biopsy sample from the proband (II-4) showed marked infiltration of the glomeruli by eosinophilic deposits. The interstitium was spared, with only focal involvement of a few small vessels (Figure 2a1). Intimately admixed with the amyloid deposits in the glomeruli were multinucleated giant cells (GCs), present singly and in loosely cohesive clusters (Figure 2a2, 2b1-2). The deposits in the glomeruli and some small vessels stained strongly positive with Congo red, exhibiting apple green birefringence under polarized light, distinctive of amyloid (Figure 2c1-2). The amyloid deposits were strongly immunoreactive with polyclonal antihuman apoA-II antibody in the glomeruli; no involvement of blood vessels or interstitium was noted (Figure 2d1-2).

The son (III-2) was diagnosed with renal amyloidosis at age 33 with serum creatinine of 1.45 mg/dl and 24-hour proteinuria of 7.4 g. At age 35, he started on peritoneal dialysis. Currently at age 36, he shows no sign of extrarenal involvement and is wait-listed for a cadaveric kidney transplant.

Identification of apoA-II in Amyloid Fibrils

Immunoelectrophoretic analysis of amyloid fibrils extracted from proband kidney tissue showed immunoreactive bands at positions similar to those observed in serum (Figure 4, lane II-4S) and consistent with the dimeric forms of apoA-II (Figure 3a). In sera from the proband and her affected children, protein bands corresponding to wild-type homodimer, wild-type and variant heterodimer, and variant homodimer apoA-II were noted. Conversely, only 1 band corresponding to wild-type homodimer was observed in unaffected family members. In the 8- to 10-kDa range, less abundant immunoreactive bands were observed in all sera indicative of monomeric apoA-II (Figure 3a, bottom panel). Under reducing conditions, sera from affected members demonstrated 2 bands in the 8- to 10-kDa region, suggesting the presence of wild-type and variant apoA-II monomers (Figure 3b). A single immunoreactive band of 8 kDa consistent with wild-type apoA-II monomer was observed in sera from unaffected members. Of note, serum from the daughter of the proband (III-1) featured wild-type apoA-II dimers and monomers of slightly different sizes compared with those identified in other affected members; no molecular weight differences in variant apoA-II species were demonstrated.

Genetic Analyses

Direct DNA sequencing of APOA2 in the proband demonstrated a heterozygous c.302G>T transversion at the second nucleotide position of the translation termination codon in exon 4; this mutation encoded leucine at position 78 of the mature apoA-II protein. Elimination of the stop codon resulted in a 21-residue extension at the C-terminal end of the variant protein, 78Leuext21 (Figure 2e). No other mutations were noted in exon 3 or the remainder of exon 4. Both children of the proband were identified as carriers of the mutation; 2 of 5 siblings were found to be negative (Figure 1, II-1 and II-3).

Analysis of Serum apoA-II Proteins

Sera from the proband and several family members were analyzed immunoelectrophoretically using a monoclonal antihuman apoA-II antibody. Under nonreducing conditions, various-sized immunoreactive bands occurred at positions on the blot corresponding to molecular weights of 15 to 21 kDa, consistent with the dimeric forms of apoA-II (Figure 3a). In sera from the proband and her affected children, protein bands corresponding to wild-type homodimer, wild-type and variant heterodimer, and variant homodimer apoA-II were noted. Conversely, only 1 band corresponding to wild-type homodimer was observed in unaffected family members. In the 8- to 10-kDa range, less abundant immunoreactive bands were observed in all sera indicative of monomeric apoA-II (Figure 3a, bottom panel). Under reducing conditions, sera from affected members demonstrated 2 bands in the 8- to 10-kDa region, suggesting the presence of wild-type and variant apoA-II monomers (Figure 3b). A single immunoreactive band of 8 kDa consistent with wild-type apoA-II monomer was observed in sera from unaffected members. Of note, serum from the daughter of the proband (III-1) featured wild-type apoA-II dimers and monomers of slightly different sizes compared with those identified in other affected members; no molecular weight differences in variant apoA-II species were demonstrated.
Figure 2. Proband (II-4) histological and genetic analyses. (a1) Light microscopy of renal parenchyma, showing marked infiltration of glomeruli by eosinophilic deposits (hematoxylin and eosin stain; original magnification, ×100). (a2) Enlarged view of boxed area in a1 panel. Clusters of multinucleated giant cells (indicated with arrows) intimately admixed with eosinophilic deposits are shown (hematoxylin and eosin stain; original magnification, ×600). (b1) Multinucleated giant cells are shown randomly dispersed throughout the glomeruli (periodic acid–Schiff stain; original magnification, ×100). (b2) Enlarged view of boxed area in b1 panel showing multinucleated giant cells (indicated with arrows) in a glomerulus (periodic acid–Schiff stain; original magnification, ×400). (c1) Congo red–positive amyloid deposits viewed by standard light microscopy (original magnification, ×100). (c2) Polarized light view of c1 section demonstrating “apple”-green birefringent property of Congo red–positive amyloid deposits (original magnification, ×100). (d1,d2) Immunohistochemistry with polyclonal human apoA-II antibody demonstrates strong positive immunoreactivity in the glomeruli (original magnifications, ×40 and ×100, respectively). No positive staining with antibodies to Ig κ or λ light chains, amyloid A, transthyretin, or apoA-I were demonstrated (data not shown). (Continued)
protein, indicative of variant homodimer (Figure 4, lane II-4f), was observed, along with 2 less intense and slightly lower sized forms of apoA-II (Figure 4, lane II-4F). Bands with approximate molecular weights of 6kDa, 8kDa, and 10kDa were suggestive of monomeric apoA-II (Figure 4, lane II-4F).

Mass Spectral Characterization of Amyloid Fibrils

Amyloid fibrils were electrophoresed under reducing conditions; 3 gel slices in the areas corresponding to the 6 kDa, 8 kDa, and 10 kDa bands observed on the immunoblot (Figure 4, asterisk [*]), were excised and subjected to mass spectral analyses. In each band, the most abundant peptides represented apoA-II protein; the number of identified apoA-II spectra was 137, 109, and 61, respectively (Figure 5a). Furthermore, peptides representing the 21-residue C-terminal extension of variant apoA-II were found, with greatest abundance in the 6-kDa band compared to the 8- and 10-kDa bands (73 vs. 58 and 30 spectra, respectively). Peptides spanning 100% of the apoA-II variant sequence were identified in the 10-kDa band and, surprisingly, in the 6-kDa bands; 93% sequence coverage was determined in the 8-kDa band (Figure 5b).

Aggregation Propensity Predictions and Secondary Structure of the apoA-II Variants

The aggregation propensity of 78Leuext21 and 3 previously reported apoA-II variants was compared using bioinformatics methods. MetaserverAmylPred2.0,22,23 identified amyloidogenic segments with a high propensity to initiate apoA-II misfolding. Consistent with previous studies, 2 hotspots located in residues 10 to 18 and 60 to 69 were present in all variants and the wild-type protein (Figure 6a)18; a third hotspot was located in the C-terminal extension of the variant proteins. The hydrophobic Leu78 residue, positioned at the edge of the C-terminal hotspot, was predicted to increase the amyloid-forming propensity of the protein and slightly extend it to residues 76 to 87 compared to residues 79 to 87 in other variants (Figure 6a).

PASTA2,24,25 analysis of apoA-II 78Leuext21 variant showed 3 aggregation-prone segments with a predicted aggregation energy below the threshold value of -5 PASTA units (Figure 6b). Two of these segments, residues 8 to 29 and 60 to 69, were located in class-A amphipathic α-helices that comprise the native structure of apoA-II on HDL and are proposed to protect wild-type apoA-II from misfolding through tight binding to HDL.18 An additional aggregation-prone segment was predicted in residues 78 to 86 of the C-terminal extension (Figure 6b). Three other apoA-II variants showed similar results, but with slightly lower aggregation propensity in the C-terminal extension compared to 78Leuext21 variant (data not shown). Compared to wild-type apoA-II, the C-terminal extension of 78Leuext21 variant was less likely to form an α-helix (Figure 6c) and much more likely to adopt a β-sheet structure (Figure 6d); this was also true of the other apoA-II variants (data not shown). Moreover, amino acid sequence analysis clearly showed that neither the α-helix nor β-sheet structures formed by the C-terminal extension was amphipathic, indicating that this domain has little if any affinity for HDL and, hence, is not protected from misfolding by the bound lipids.

**DISCUSSION**

We describe a female patient of Filipino-Portuguese descent with hereditary renal amyloidosis caused by a novel heterozygous mutation in the translation termination codon of APOA2 that results in replacement of the stop codon with leucine and expression of a variant protein with a 21-amino acid residue C-terminus extension, apoA-II 78Leuext21. AApoAII amyloidosis was first reported in 2 sisters with nephropathy13; 28 years later, renal amyloidosis was reported in 2 brothers...
from the third generation of this family, and full-length apoA-II 78Glyext21 was identified as the fibril constituent in the amyloid deposits. In total, 4 heterozygous APOA2 stop codon mutations have been described; all encoded protein variants that were associated with renal amyloidosis (Table 1). The 78Argext21 variant has been detailed in Armenian and Spanish males, each with family history of nephropathy; the 78Serext21 variant was reported in a Caucasian male with no family history. In all cases, disease manifested in the fourth and fifth decades of life (Table 1). Interestingly, renal amyloidosis caused by wild-type apoA-II has been reported in a Japanese male, but clinical symptoms were not observed until the seventh decade.26

Similar to previous reports, the 78Leuext21 variant featured renal disease characterized by nephrotic range proteinuria and elevated creatinine with progression to end-stage renal disease (ESRD). The time from diagnosis to ESRD ranged from 3 years in the proband II-4 to 6 and 2 years in her affected children, III-1 and III-2, respectively. A longer progression to ESRD, ranging from 18 years in the proband to 8 and 12 years in 2 affected children, was noted in the 78Glyext21 series (Table 1). Moreover, in AApoAII-78Argext21, the patient had not reached ESRD after a 22-year course of renal disease, suggesting that protein sequence, specifically the amino acid at residue 78, is linked to the rate of disease progression.

The first case of successful renal transplantation with stable graft function over 9-year follow-up was reported in a patient with 78Glyext21 variant (Table 1). In our cases II-4 and III-1, the graft remains functioning 14 and 2 years posttransplantation. The slow decline in renal function with microalbuminuria in proband II-4 is likely caused by chronic allograft nephropathy.

Indicators of amyloid cardiomyopathy as demonstrated by EKG, echocardiography, and 99mTc-pyrophosphate scintigraphy were reported in a patient with the 78Argext21 variant 20 years after the initial disease presentation (Table 1). Another case of AApoAII-associated cardiomyopathy has been reported recently;
however, neither clinical nor genetic information was provided. Although no clinical evidence of extrarenal involvement was demonstrated in our or other reports of AApoAII amyloidosis, extrarenal amyloid deposits were found either accidentally or at postmortem evaluation (Table 2). Autopsy results from the 78Glyext21 series revealed modest deposits in multiple organs from 2 individuals. In all cases of AApoAII amyloidosis, the amyloid was located predominantly in the glomeruli, with modest deposition noted in a few blood vessels and rare peritubular deposits (Table 2). Immunohistochemistry with antihuman apoA-II antibody demonstrated positive glomerular staining that colocalized with the amyloid deposits. A similar pattern of renal amyloid distribution confined to the glomeruli is featured in fibrinogen A-α chain amyloidosis, whereas the glomerular compartment is spared in apoA-IV and leukocyte chemotactic factor 2 amyloidoses.

---

**Figure 5.** Proteomic study of kidney-derived amyloid fibrils using mass spectrometry. (a) Scaffold readout of the top 30 proteins identified in excised gel slices containing 6 kDa, 8 kDa, and 10 kDa apoA-II fibril proteins (Figure 4, asterisk [*]). The number in the box denotes the number of spectra obtained on each sample for each identified protein. Green highlighting denotes >95% probability for protein identification. ApoA-II is designated with a blue star and occurs as the #2 entry on the list; data show high abundance of the apoA-II in each sample, and the >95% probability suggests strong confidence in the accuracy of the data. Universal amyloid tissue biomarker proteins, apolipoprotein E, and serum amyloid P-component are each designated with an orange star and detected in all 3 samples; apolipoprotein A-IV is also detected at low levels (#56 entry on scaffold readout table) and is not shown. Peptides representing several other amyloid-forming proteins, transthyretin, lysozyme C, Ig κ light chain, and Ig heavy chain were detected in low amounts; there was no evidence of other known amyloidogenic precursor proteins associated with renal amyloidosis. (b) ApoA-II sequence coverage demonstrated in the 6 kDa, 8 kDa, and 10 kDa proteins. Peptides accounting for 100% of the variant ApoA-II sequence (shown on yellow background) are identified in the 6-kDa and 10-kDa samples; 93% sequence coverage is obtained in the 8-kDa sample; the peptide FQTVTDY, indicated with black triangles, is not detected. The proAPOA-II peptide, ALVRR (shown on white background), is not detected in any of the samples. The C-terminal extension sequence of variant apoA-II, LSVTIVFGPQLASRTPTGQS, is underlined. Residues, highlighted in green, denote artifactual modifications (pyro glutamic acid formation of N-terminal glutamine or oxidation of methionine, correspondingly) induced by sample processing.

---

| #  | Tissue | Identified Proteins (313) |
|----|-------|--------------------------|
| 1  | Kidney | Actin, aortic smooth muscle |
| 2  | Kidney | Apolipoprotein A-II mutant extension |
| 3  | Kidney | Apolipoprotein A-II |
| 4  | Kidney | Isf34 of Glycogen 1 |
| 5  | Kidney | Serine alphakinase 1 |
| 6  | Kidney | Apolipoprotein A-II |
| 7  | Kidney | Apolipoprotein A-II |
| 8  | Kidney | Apolipoprotein A-II |
| 9  | Kidney | Apolipoprotein A-II |
| 10 | Kidney | Apolipoprotein A-II |
| 11 | Kidney | Apolipoprotein A-II |
| 12 | Kidney | Apolipoprotein A-II |
| 13 | Kidney | Apolipoprotein A-II |
| 14 | Kidney | Apolipoprotein A-II |
| 15 | Kidney | Apolipoprotein A-II |
| 16 | Kidney | Apolipoprotein A-II |
| 17 | Kidney | Apolipoprotein A-II |
| 18 | Kidney | Apolipoprotein A-II |
| 19 | Kidney | Apolipoprotein A-II |
| 20 | Kidney | Apolipoprotein A-II |
| 21 | Kidney | Apolipoprotein A-II |
| 22 | Kidney | Apolipoprotein A-II |
| 23 | Kidney | Apolipoprotein A-II |
| 24 | Kidney | Apolipoprotein A-II |
| 25 | Kidney | Apolipoprotein A-II |
| 26 | Kidney | Apolipoprotein A-II |
| 27 | Kidney | Apolipoprotein A-II |
| 28 | Kidney | Apolipoprotein A-II |
| 29 | Kidney | Apolipoprotein A-II |
| 30 | Kidney | Apolipoprotein A-II |

**APOA2_HUMAN (100%), 10,948.4 Da**

**Apolipoprotein A-II mutant extension**

---

[Table and diagram images are not shown in the text representation.]
Figure 6. *In silico* predictions of ApoA-II aggregation and secondary structure propensities. (a) Prediction of amyloid-forming hotspots is accomplished using the consensus meta-server AmylPred2.22,23 The amino acid sequences of wild-type and amyloidogenic apoA-II variants are shown. Residues 1 to 77 correspond to wild-type apoA-II, and residues 78 to 98 represent the C-terminal extensions of variant proteins; the signal peptide is not included. The different residues located at position 78 in the apoA-II variants are shown in underscored bold and indicated with black arrow. Amyloidogenic residue segments predicted by a consensus of at least 5 of 11 methods are shown in red italics. (b) Prediction of amyloid-forming hotspots is accomplished using the sequence-based bioinformatics program PASTA2.018,24,25; the results are plotted as a function of the residue number. Aggregation-free energy is shown in PASTA units (1 unit of aggregation propensity is accomplished using the sequence-based bioinformatics program PASTA2.018,24,25; the results are plotted as a function of the residue number. Aggregation-free energy is shown in PASTA units (1 unit = 1.192 kcal/mol).25 Favorable free energy that exceeds the threshold of −5 PASTA units is indicated by a gray horizontal line. High aggregation propensity is predicted for residue segments 8 to 29, 60 to 69, and 78 to 86. (c) α-Helix probability. (d) β-Strand probability. β-Strand probability is shown in black line, and amyloidogenic propensity is shown in gray.

An intriguing histological feature in the proband II-4 was the presence of numerous GCs located adjacent to the glomerular amyloid deposits. Similar findings were originally described in 2 siblings with AApoAII 78Glyext2113; however, no GCs were observed in the current case III-1 or in other reports (Table 2). Multinucleated GCs are frequently found in localized30 and, occasionally, systemic amyloidoses.31,32 Resulting from the fusion of macrophages, GCs are considered to function as phagocytes in the resorption of amyloid deposits, but rarely succeed in the spontaneous clearance of the fibrils.33

Consistent with the heterozygous nature of the APOA2 stop codon mutation, both wild-type and variant apoA-II proteins were found in sera from affected members in our study. Multiple dimeric forms of apoA-II most likely representing the wild-type homodimer, wild-type and variant heterodimer, and variant homodimer were detected in the samples.14–16 Similar to other reports, the reduction of dimeric apoA-II yielded wild-type and variant monomers with molecular weights of approximately 8 and 10 kDa.

The nonvariant protein in serum from affected member III-1 exhibited a slightly higher size compared to wild-type bands identified in other affected members II-4 and III-2 (Figure 3a, b). The increased molecular weight, presumably, of the wild-type protein, may be due to the presence of pro–apoA-II, a mature form of the protein with a 5-residue pro-peptide (Figure 5b). A small quantity of pro–apoA-II has been reported in human circulation,34 and the intact pro–apoA-II was found in amyloid deposits from a senescence accelerated mouse model of aging.35 Nonetheless, there is no report of pro–apoA-II deposition in AApoAII amyloidosis and we have no evidence to support this speculation as amyloid fibril material was not available for analysis on this case.

Immunoelectrophoretic analysis of amyloid fibrils from the proband II-2 showed multiple monomorphic and dimeric apoA-II species. Three bands with molecular weights of 6, 8, and 10 kDa consistent with monomeric apoA-II were subjected to mass spectral analysis. Each sample demonstrated peptides that covered the entire 21-residue C-terminal extension of variant apoA-II and essentially yielded full-length protein coverage. The mass spectral data suggest that the entire 78Lueext21 variant is a major constituent of amyloid deposits in the proband. These results are in agreement with previous studies that reported full-length monomeric 78Argext21 and 78Glyext21 variants as major components of amyloid deposits.14,16 The presence of the variant apoA-II homodimer in the deposits of our

| Residue Number | WT     | 78Lueext21 | 78Argext21 | 78Glyext21 |
|----------------|--------|------------|------------|------------|
| 1              | QAKEPCVESL | QAKEPCVESL | QAKEPCVESL | QAKEPCVESL |
| 2              | VSQYFOQTVTD | VSQYFOQTVTD | VSQYFOQTVTD | VSQYFOQTVTD |
| 3              | YGKDLMEKKK | YGKDLMEKKK | YGKDLMEKKK | YGKDLMEKKK |
| 4              | SPELQAEEKS | SPELQAEEKS | SPELQAEEKS | SPELQAEEKS |
| 5              | YFEKSEQLT  | YFEKSEQLT  | YFEKSEQLT  | YFEKSEQLT  |
| 6              | PLIKKAGTEL | PLIKKAGTEL | PLIKKAGTEL | PLIKKAGTEL |
| 7              | VNFLSYFVEL | VNFLSYFVEL | VNFLSYFVEL | VNFLSYFVEL |
| 8              | GTQPATQ    | GTQPATQ    | GTQPATQ    | GTQPATQ    |
| 9              |          |            |            |            |
| 10             |          |            |            |            |
| 11             |          |            |            |            |
| 12             |          |            |            |            |
| 13             |          |            |            |            |
| 14             |          |            |            |            |
| 15             |          |            |            |            |
| 16             |          |            |            |            |
| 17             |          |            |            |            |
| 18             |          |            |            |            |
| 19             |          |            |            |            |
| 20             |          |            |            |            |
| 21             |          |            |            |            |
| 22             |          |            |            |            |
| 23             |          |            |            |            |
| 24             |          |            |            |            |
| 25             |          |            |            |            |
| 26             |          |            |            |            |
| 27             |          |            |            |            |
| 28             |          |            |            |            |
| 29             |          |            |            |            |
| 30             |          |            |            |            |
| 31             |          |            |            |            |
| 32             |          |            |            |            |
| 33             |          |            |            |            |
| 34             |          |            |            |            |
| 35             |          |            |            |            |
| 36             |          |            |            |            |
| 37             |          |            |            |            |
| 38             |          |            |            |            |
| 39             |          |            |            |            |
| 40             |          |            |            |            |
| 41             |          |            |            |            |
| 42             |          |            |            |            |
| 43             |          |            |            |            |
| 44             |          |            |            |            |
| 45             |          |            |            |            |
| 46             |          |            |            |            |
| 47             |          |            |            |            |
| 48             |          |            |            |            |
| 49             |          |            |            |            |
| 50             |          |            |            |            |
| 51             |          |            |            |            |
| 52             |          |            |            |            |
| 53             |          |            |            |            |
| 54             |          |            |            |            |
| 55             |          |            |            |            |
| 56             |          |            |            |            |
| 57             |          |            |            |            |
| 58             |          |            |            |            |
| 59             |          |            |            |            |
| 60             |          |            |            |            |
| 61             |          |            |            |            |
| 62             |          |            |            |            |
| 63             |          |            |            |            |
| 64             |          |            |            |            |
| 65             |          |            |            |            |
| 66             |          |            |            |            |
| 67             |          |            |            |            |
| 68             |          |            |            |            |
| 69             |          |            |            |            |
| 70             |          |            |            |            |
| 71             |          |            |            |            |
| 72             |          |            |            |            |
| 73             |          |            |            |            |
| 74             |          |            |            |            |
| 75             |          |            |            |            |
| 76             |          |            |            |            |
| 77             |          |            |            |            |
| 78             |          |            |            |            |
| 79             |          |            |            |            |
| 80             |          |            |            |            |
| 81             |          |            |            |            |
| 82             |          |            |            |            |
| 83             |          |            |            |            |
| 84             |          |            |            |            |
| 85             |          |            |            |            |
| 86             |          |            |            |            |
| 87             |          |            |            |            |
| 88             |          |            |            |            |
| 89             |          |            |            |            |
| 90             |          |            |            |            |
| 91             |          |            |            |            |
| 92             |          |            |            |            |
| 93             |          |            |            |            |
| 94             |          |            |            |            |
| 95             |          |            |            |            |
| 96             |          |            |            |            |
| 97             |          |            |            |            |
| 98             |          |            |            |            |
patient suggests that fibril formation does not necessarily occur after apoA-II dimer reduction as previously hypothesized.\(^1\) The nature of the less abundant dimeric apoA-II forms remains unclear. Although these bands occurred at positions corresponding to wild-type apoA-II dimer, our data neither confirm nor refute the

## Table 1. Genetic, demographic, and clinical characteristics of cases with AApoAII amyloidosis

| Characteristic                                                                 | 78Leu\(^{ex21}\) Current report | 78Arg\(^{ex21}\) Current report | 78Ser\(^{ex21}\) Current report | 78Gly\(^{ex21}\) Current report | 78Ter\(^{ex21}\) Current report |
|-------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Sequence variant (mRNA)                                                      | c.302G>T                        | c.301T>C                        | c.302G>T                        | c.301T>C                        | c.301T>G                        |
| Ethnicity                                                                    | Filipino-Portuguese             | Armenian                        | Spanish                         | Caucasian                       | American                        |
| Proband: age at disease onset, yr; gender                                    | II-4: 41F                       | 34M                             | No data M                       | 42M                             | II.2: 33F                       |
|                                                                             |                                  |                                 |                                 |                                 | II.4: 42F                       |
|                                                                             |                                  |                                 |                                 |                                 | 67M                             |
| Affected family members: age at disease onset, yr; gender                    | III-1: 30F                      | 3                              | 0                               | None                            | III.1: Late 20\(^{th}\) M       |
|                                                                             | III-2: 33M                      |                                 |                                 |                                 | III.2: 34M                      |
| Renal involvement                                                            |                                  |                                 |                                 |                                 |                                 |
| 24-h proteinuria at initial evaluation, g                                   | II-4: 13                        | 3                              | No data                         | 0.6                             | II.2: 3                           |
|                                                                             | III-1: 2.7                      |                                 |                                 |                                 | II.4: 3.3                       |
|                                                                             | III-2: 7.4                      |                                 |                                 |                                 | III.1: no data                  |
|                                                                             |                                  |                                 |                                 |                                 | III.2: no data                  |
| Time from first symptom to ESRD, yr                                         | II-4: 3                         | +                              | +                               | +                               | II.2: 18                         |
|                                                                             | III-1: 6                        | +                              | +                               | +                               | II.4: 18                         |
|                                                                             | III-2: 2                        |                                 |                                 |                                 | III.1: 8                        |
|                                                                             |                                  |                                 |                                 |                                 | III.2: 12                       |
| Kidney transplant                                                            | II-4: +                         | None                            | Wait list                       | II.2: +                         |
|                                                                             | III-1: +                        |                                 |                                 | +                               | II.4: +                         |
|                                                                             | III-2: wait list                |                                 |                                 | +                               | III.1: +                        |
|                                                                             |                                  |                                 |                                 | +                               | III.2: +                        |
| Posttransplantation follow-up, yr                                           | II-4: 14                        | –                              | –                               | II.2: acute graft rejection      |
|                                                                             | III-1: 2                        | –                              | –                               | III.1: 9                        |
|                                                                             |                                  |                                 |                                 | III.2: acute graft rejection     |
| Extrarenal involvement                                                       | None                            | Cardiac                        | None                            | None                            | None                            |
| Disease duration: first symptom to the end of observation, yr               | II-4: 19                        | 22                             | No data                         | 4                               | II.2: 19                         |
|                                                                             | III-1: 11                       |                                 |                                 | II.4: 5                         |
|                                                                             | III-2: 3                        |                                 |                                 | III.1: 22                       |
|                                                                             |                                  |                                 |                                 | III.2: 17                       |
| Cause of death                                                               | –                               | –                              | –                               | II.2: Klebsiella pneumonia       |
|                                                                             |                                  |                                 |                                 | II.4: Renal failure             |
|                                                                             |                                  |                                 |                                 | III.2: Sepsis                    |
| II-4, III-1, and III-2 indicate the proband and her affected children described in current report. II.2 and II.4 (reference\(^7\)), III.1 and III.2 (references\(^14,27\)) indicate probands and affected family members with 78Gly\(^{ex21}\) variant. F, female; M, male; ESRD, end-stage renal disease.
*Father of the proband, 53 years old, died of renal failure; a parental half-brother, 45 years old has renal failure.
*Four sisters and a nephew of the proband feature nephropathy.
*ESRD was not reached at the end of follow-up observation.
*ESRD was reached at the end of follow-up observation.

## Table 2. Histological features and biochemical characteristics of amyloid fibrils in cases with AApoAII amyloidosis

| Characteristic                                                                 | 78Leu\(^{ex21}\) Current report | 78Arg\(^{ex21}\) Current report | 78Ser\(^{ex21}\) Current report | 78Gly\(^{ex21}\) Current report | 78Ter\(^{ex21}\) Current report |
|-------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Kidney amyloid deposits                                                      | II-4: Marked GM; small vascular | GM; vascular                     | GM; vascular                     | GM; vascular                     | GM; small vascular               |
| Multinucleated giant cells                                                   | II-4: GM                        | None                            | None                            | GM                              | None                            |
| Extrarenal amyloid deposits                                                  | II-4, III-2: Fat                | Skin and rectum: vascular       | None                            | Fat and bone marrow: vascular    | None                            |
| Kidney: IHC with apoA-II antibody                                            | GM staining                     | Not done                        | Not done                        | Not done                        | GM staining                     |
| Amyloid deposits characterization                                             | II-4: Full-length apoA-II variant | ApoA-II variant                 | Not done                        | Not done                        | III.2: Full-length apoA-II variant | Not done                        |

II-4, III-1, and III-2 indicate the proband and her affected children described in current report. II.2 and II.4, (reference\(^7\)), III.1 and III.2 (references\(^14,27\)) indicate probands and affected family members with 78Gly\(^{ex21}\) variant. GI, gastrointestinal; GM, glomerular; IHC, immunochistochemistry. *Adrenal gland, liver, spleen, heart, and thyroid gland tissues were negative for amyloid deposits.
*Confirmed by mass spectral analysis.
*Confirmed by western blot analysis.
*Confirmed by western blot and Edman degradation analyses.
presence of the wild-type protein in the deposits. It is possible that these are truncated forms of dimeric variant apoA-II.

Although all apoA-II variants were predicted to have similar amyloid hotspots, the segment located in the C-terminal extension of apoA-II 78Leuext21 had a slightly higher aggregation propensity than other mutants, likely due to the highly hydrophobic nature of leucine (Figure 6). We speculate that the increased hydrophobicity of leucine-containing C-terminal extension may contribute to more rapid progression to ESRD compared to other variants (Table 1). Moreover, the C-terminal extension of the 78Leuext21 variant was also predicted to have a greatly increased propensity to form β-sheet and lower α-helical propensity compared to the rest of the apoA-II molecule (Figure 6c, d). Importantly, neither the β-strand nor the α-helix formed by the C-terminal extension is amphipathic. Therefore, unlike the rest of the apoA-II molecule, the amyloid hotspot located in the C-terminal extension is not protected from aggregation and is likely to trigger the release of apoA-II from HDL and initiate protein misfolding from the highly helical native conformation on HDL to the intermolecular β-sheet in amyloid.

In conclusion, we report a kinship with AF renal amyloidosis caused by a novel apoA-II 78Leuext21 variant. The disease is characterized by renal dysfunction progressing to ESRD due to glomerular amyloid deposits comprising full-length apoA-II variant. A segment of the variant protein located within the leucine-containing C-terminal extension is predicted to have a slightly higher aggregation propensity compared to other amyloidogenic variants and may contribute to more rapid progression of kidney disease. The study indicates that AApoAII amyloidosis should be considered in the differential diagnosis of patients with hereditary renal disease.

Tatiana Prokaeva1, Harun Akar2, Brian Spencer1, Andrea Havasi1,3, Haili Cui1,4, Carl J. O’Hara1,4, Olga Gursky1,5, John Leszyk6, Martin Steffen4, Sabrina Browning1, Allison Rosenberg1 and Lawrene H. Connors1,4

1Amyloidosis Center, Boston University School of Medicine, Boston, Massachusetts, USA; 2Tepecik Education and Research Hospital, Internal Medicine Clinic, Izmir, Turkey; 3Department of Nephrology, Boston University School of Medicine, Boston, Massachusetts, USA; 4Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA; 5Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts, USA; and 6Proteomics and Mass Spectrometry Facility and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Correspondence: Tatiana Prokaeva, Amyloidosis Center, Boston University School of Medicine, 72 East Concord Street, K-510, Boston, Massachusetts 02118-2526, USA. prokaeva@bu.edu

DISCLOSURE

All the authors declared no competing interests.

ACKNOWLEDGMENTS

This study was supported by the National Institutes of Health grants KO8DK090143 (AH) and GM067260 (OG); the Wildflower Foundation and the Gruss Foundation; the Stewart Amyloidosis Endowment Fund, the Young Family Amyloidosis Endowment Fund, and the Amyloidosis Research Fund at Boston University; fellowship from the Turkish Society of Nephrology (HA). The funding organizations had no role in study design; data collection; results interpretation; writing the manuscript; and decision to submit. We acknowledge all past and present members of the Amyloidosis Center clinical team who took care of patients included into the study and patients who provided serum and tissue samples for this study. The part of this work, specifically genetic analyses of APOA2 in the prote band II-4, was reported in an extended abstract at the Xth International Symposium on Amyloidosis in Tours, France, 18–22 April 2004.

SUPPLEMENTARY MATERIAL

Supplementary Materials and Methods.

Table S1. Primer sequences for polymerase chain reaction amplification of APOA2 gene.

Supplementary material is linked to the online version of the paper at www.kireports.org.

REFERENCES

1. Hawkins PN. Hereditary systemic amyloidosis with renal involvement. J Nephrol. 2003;16:443–448.
2. Sattianayagam PT, Gibbs SDJ, Rowcenio D, et al. Hereditary lysozyme amyloidosis —phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med. 2012;272:36–44.
3. Ostertag B. Demonstration einer Eigenartigen familiaren paramyloidose. Zentralbl Aug Pathol. 1932;56:253–254.
4. Benson MD. Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid. 2005;12:75–87.
5. Gillmore JD, Lachmann HJ, Rowcenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2009;20:444–451.
6. Stangou AJ, Banner NR, Hendry BM, et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. 2010;115:2998–3007.
7. Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017;32:770–780.
8. Kiuru-Enari S, Haltia M. Hereditary gelsolin amyloidosis. Handb Clin Neurol. 2013;115:659–681.

9. Sethi S, Theis JD, Shiller SM, et al. Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int. 2012;81:201–206.

10. Dasari S, Amin MS, Kurtin PJ, et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int. 2016;90:658–664.

11. Nasr SH, Dasari S, Hasadsri L, et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol. 2017;28:439–445.

12. Valleix S, Verona G, Jourde-Chiche N, et al. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun. 2016;7:10353.

13. Weiss SW, Page DL. Amyloid nephropathy of Ostertag with special reference to renal glomerular giant cells. Am J Pathol. 1973;72:447–460.

14. Benson MD, Liepnieks JJ, Yazaki M, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein All gene. Genomics. 2001;72:272–277.

15. Yazaki M, Liepnieks JJ, Yamashita T, et al. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int. 2001;60:1658–1665.

16. Yazaki M, Liepnieks JJ, Barats MS, et al. Hereditary systemic amyloidosis associated with a new apolipoprotein All stop codon mutation Stop78Arg. Kidney Int. 2003;64:11–16.

17. De Gracia R, Fernández EJ, Riñón C, et al. Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein All gene. Q J Med. 2006;99:274.

18. Gursky O. Hot spots in apolipoprotein A-II misfolding and amyloidosis in mice and men. FEBS Lett. 2014;588:845–850.

19. Gursky O. Structural stability and functional remodeling of high-density lipoproteins. FEBS Lett. 2015;589:2627–2639.

20. Gursky O, Atkinson D. High- and low-temperature unfolding of human high-density apolipoprotein A-2. Protein Sci. 1996;5:1874–1882.

21. Das M, Gursky O. Amyloid-forming properties of human apolipoproteins: sequence analyses and structural insights. Adv Exp Med Biol. 2015;855:175–211.

22. Hamodrakas SJ, Liappa C, Icomimidou VA. Consensus prediction of amyloidogenic determinants in amyloid fibril-forming proteins. Int J Biol Macromol. 2007;41:295–300.

23. Tsolis AC, Papandreou NC, Icomimidou VA, et al. A consensus method for the prediction of “aggregation-prone” peptides in globular proteins. PLoS One. 2013;8:e54175.